Tolerability and pharmacokinetics of intravitreal sirolimus

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 5, 2012, Pages 507-514

  Mudumba, Sri ^a   Bezwada, Padma ^a   Takanaga, Hitomi ^a   Hosoi, Kazuhiro ^a   Tsuboi, Takashi ^a   Ueda, Kenji ^a   Kawazu, Kouichi ^a   Ali, Yusuf ^a   Naor, Joel ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ARTICLE; BLOOD SAMPLING; CATARACT; CHOROID; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EUTHANASIA; FEMALE; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RABBIT; SCLERA; TANDEM MASS SPECTROMETRY; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CHROMATOGRAPHY, LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RABBITS; SIROLIMUS; TANDEM MASS SPECTROMETRY; TIME FACTORS; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 84867017672     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0226     Document Type: Article

References (22)

1. Anglade, E., Yatscoff, R., Foster, R., and Grau, U. Nextgeneration calcineurin inhibitors for ophthalmic indications. Exp. Opin. Investig. Drugs 16:1525-1540, 2007.
2. Kulkarni, P. Review: uveitis and immunosuppressive drugs. J. Ocul. Pharmacol. 17:181-187, 2001.
3. Shanmuganathan, V., Casely, E., Raj, D., Powell, R., Joseph, A., Amoaku, W., and Dua, H. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br. J. Ophthalmol. 89:666-669, 2005.
4. Phillips, B., and Wroblewski, K. A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. J. Ophthalmic. Inflamm. Infect. 1:29-34, 2011.
5. Napoli, K., and Taylor, P. From beach to bedside: history of the development of sirolimus. Therapeut. Drug Monit. 23: 559-586, 2001.
6. Sehgal, S. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockage of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31:335-340, 1998.
7. Kwon, Y., Hong, H., Kim, J., Shin, J., and Son, Y. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 46:454-460, 2005.
8. Sehgal, S. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Therapeut. Drug Monit.17:660-665, 1995.
9. Rapamune (sirolimus) Oral Solution and Tablets, approval in 1999, Wyeth Pharmaceutical Inc. Philadelphia, PA (Package Insert).
10. CYPHER-Sirolimus-eluting Coronary Stent on RAPTOR-Over-the-Wire Delivery System and CYPHER-Sirolimuseluting Coronary Stent on RAPTORRAIL Rapid Exchange Delivery System, approval in 2003, Cordis Corporation, Bridgewater, NJ (Package Insert).
11. Barton, K., McLauchlan, M., Calder, V., and Lightman, S. The kinetics of cytokine mRNA expression in the retina during experimental autoimmune uveoretinitis. Cell. Immunol. 164:133-140, 1995.
12. Ikeda, E., Hikita, N., Eto, K., and Mochizuki, M. Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. Jpn. J. Ophthalmol. 41:396-402, 1997.
13. Martin, D., DeBarge, L., Nussenblatt, R., Chan, C., and Roberge, F. Synergistic effect of rapamycin and cyclosporin A on the inhibition of experimental autoimmune uveoretinitis. Uveitis 154:922-997, 1995.
14. Roberge, F., Xu,D., Chan, C., de Smet,M., Nussenblatt, R., and Chen, H. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr. Eye Res. 12:197-203, 1993.
15. Young, S., Larking, G., Branley, M., and Lightman, S. Safety and efficacy of intravitreal triamcinolone for cystoid macular odema in uveitis. Clin. Exp. Ophthalmol. 29:2-6, 2001.
16. Antcliff, R., Spalton, D., Stanford, M., Graham, E., Ffyche, T., and Marshall, J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765-772, 2001.
17. Jonas, J., Degenring, R., Kresissig, I., and Akkoyun, I. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am. J. Ophthalmol. 138:1054-1055, 2004.
18. Groth, C., Backman, L., Morales, J., Calne, R., Kreis, H., Lang, P., Touraine, J., Claesson, K., Campistol, J., Durand, D., Wramner, L., Brattstrom, C., and Charpentier, B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67:1036-1042, 1999.
19. MacDonald, A., Scarola, J., Burke, J., and Zimmerman, J. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin. Therapeut. 22:B101-B121, 2000.
20. Manzano, R., Peyman, G., Khan, P., Kivilcim, M., Chevez-Barrios, P., and Takahashi, W. Testing intravitreal toxicity of rapamycin in rabbit eyes. Arquivos Brasileiros de Oftalmologia 72:18-22, 2009.
21. Douglas, L., Yi, N., Davis, J., Salmon, J., and Gilger, B. Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J. Vet. Pharmacol. Therapeut. 31:511-516, 2008.
22. Ibrahim, M., Watters, A., Rentiya, Z., Sepah, Y., Leder, H., Hatef, E., Naor, J., Shams, N., Dunn, J., and Nguyen, Q. Sirolimus as therapeutic approach to uveitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with noninfectious uveitis (the save study). Abstract. Association for Research in Vision and Ophthalmology Annual Meeting, Ft Lauderdale, FL, May 2011.